REPL — Replimune Group, Inc.

Is REPL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Replimune Group, Inc. (REPL) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $15.58. The rating moved from Neutral to Overbought on August 4, 2026.

See all overbought Healthcare stocks →

AI analysis

Replimune Group, Inc. (REPL) is positioned as a clinical-stage oncology biotech with promising oncolytic immunotherapy assets and near-term data catalysts that could materially affect equity value. Recent positive sentiment in the biologics/oncology complex and a risk-on market backdrop improve the probability of constructive price action in the near term, while underlying upside remains tied to clinical readouts, partner engagements, and balance-sheet management. The company faces typical biotech downside risks—trial outcomes, regulatory timing, cash burn and dilution—but could generate meaningful revaluation if key studies demonstrate favorable efficacy and safety or if strategic collaborations expand development and commercialization pathways.

Key factors

  • Late-stage and mid-stage clinical pipeline in oncolytic immunotherapies (e.g., RP1) with potential near-term data readouts that could re-rate the stock
  • Sector readthrough from positive mRNA/biologics oncology data supporting investor appetite for novel oncology platforms and biologics suppliers
  • Favorable short-term market tone (risk-on) that supports momentum in growth/biotech names
  • Partnerships and platform leverage potential to broaden indications and combination therapy opportunities
  • Reasonable cash runway assumptions relative to upcoming milestones (subject to confirmed filings) that reduce immediate dilution risk
  • Limited social sentiment currently, which reduces crowd-driven volatility but keeps upside tied to fundamentals and clinical newsflow

Risks

  • Clinical trial failures or disappointing efficacy/safety readouts for lead programs
  • High cash burn and potential for equity dilution if additional financing is required
  • Regulatory setbacks or prolonged review timelines for oncology assets
  • Intense competition in oncology biologics and oncolytic space from larger, better-funded peers
  • Payer/reimbursement pressure and shifts in commercialization strategy impacting future revenue realization
  • Macro/geopolitical-driven market volatility that can sharply reprice speculative biotech names
  • Limited current commercial revenue base makes valuation highly dependent on binary clinical outcomes

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for REPL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.